TG Therapeutics, Inc.TGTXNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
-15.72%
↓ 202% below average
Average (39q)
15.42%
Historical baseline
Range
High:356.94%
Low:-110.88%
CAGR
-1.4%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -15.72% |
| Q2 2025 | 304.12% |
| Q1 2025 | -71.21% |
| Q4 2024 | 140.86% |
| Q3 2024 | 41.04% |
| Q2 2024 | 195.10% |
| Q1 2024 | 25.75% |
| Q4 2023 | -110.88% |
| Q3 2023 | 356.94% |
| Q2 2023 | -20.77% |
| Q1 2023 | 28.95% |
| Q4 2022 | -48.91% |
| Q3 2022 | 10.22% |
| Q2 2022 | 41.77% |
| Q1 2022 | 28.05% |
| Q4 2021 | -9.18% |
| Q3 2021 | -9.85% |
| Q2 2021 | 13.13% |
| Q1 2021 | -2.79% |
| Q4 2020 | -1.24% |
| Q3 2020 | -68.59% |
| Q2 2020 | -1.19% |
| Q1 2020 | -32.36% |
| Q4 2019 | 37.63% |
| Q3 2019 | -71.23% |
| Q2 2019 | -2.46% |
| Q1 2019 | 35.94% |
| Q4 2018 | -57.74% |
| Q3 2018 | 22.59% |
| Q2 2018 | -6.66% |
| Q1 2018 | -33.97% |
| Q4 2017 | 1.74% |
| Q3 2017 | -11.12% |
| Q2 2017 | -2.74% |
| Q1 2017 | -15.14% |
| Q4 2016 | 3.60% |
| Q3 2016 | -55.56% |
| Q2 2016 | -14.52% |
| Q1 2016 | 20.68% |
| Q4 2015 | -27.59% |